Description
XERMELO 250 MG
First action · last action
2017-07-25 · 2017-07-25
Transactions
1
First transaction's obligation
$3,865
Base + all options value (sum of deltas)
$3,865
Extent competed
COMPETED UNDER SAP
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
NAICS
339113 · SURGICAL APPLIANCE AND SUPPLIES MANUFACTURING
Modification chain · 1 transaction
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2017-07-25+$3,865= $3,865
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2017-07-25 | +$3,865 | $3,865 | XERMELO 250 MG |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI GVRYEDLFU6J3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C26126P0068 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $29,628 | FY2026 |
| 36C26125P1616 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $18,697 | FY2025 |
| 36C26125P1544 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $77,456 | FY2025 |
| 36C25925P1069 | NETWORK CONTRACT OFFICE 19 (36C259) · 6505 · DRUGS AND BIOLOGICALS | $10,035 | FY2025 |
| 36C26223P0842 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36C24222P0293 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $10,296 | FY2022 |
Other recipients under 6505 from 512-BALTIMORE(00512)(36C512) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA24517F3805 | LEADIANT BIOSCIENCES, INC. | 512-BALTIMORE(00512)(36C512) | $3,859 | FY2017 |
| VA24517P3746 | MCKESSON CORPORATION | 512-BALTIMORE(00512)(36C512) | $18,959 | FY2017 |
| VA24517P3716 | EXPRESS SCRIPTS INC | 512-BALTIMORE(00512)(36C512) | $6,029 | FY2017 |
| VA24517P1032 | MCKESSON CORPORATION | 512-BALTIMORE(00512)(36C512) | $31,073 | FY2017 |
| VA24517F3806 | UNITED THERAPEUTICS CORP | 512-BALTIMORE(00512)(36C512) | $9,036 | FY2017 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA24517P3719_3600_-NONE-_-NONE- · retrieved 2026-09-26.